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Summary.-Concentrations of misonidazole and its 0-demethylated metabolite
Ro 05-9963 in the plasma and saliva of 10 patients with malignant disease have been
determined. A good linear correlation was established between plasma and saliva
misonidazole concentration, and salivary sampling was found to be suitable for the
estimation of a number of pharmacokinetic parameters. Data are also presented for
serial tumour concentrations of misonidazole and Ro 05-9963 in 3 of the 10 patients.
Monitoring of salivary misonidazole concentration appears to be a useful alternative
to plasma monitoring, particularly for those patients in whom plasma sampling is
unsuitable or impossible.
THE HYPOXIC CELL RADIOSENSITIZER,
misonidazole (MIS; 1 - (2 - nitroimidazol -
l-yl-3-methoxypropan-2-ol; NSC-261037;
Ro 07-0582, Roche Laboratories), is
currently under clinical investigation at a
number of radiotherapy centres. In pre-
vious clinical studies (Dische et al., 1977;
Urtasun et al., 1977; Wiltshire et al., 1978)
plasma MIS concentrations have been
determined and this was found to be
important for 2 reasons. Firstly, the
radiation enhancement ratio for hypoxic
cells is dependent upon MIS concentration
(Asquith et al., 1974). Although reported
tumour concentrations in man vary from
12-107°, of the corresponding plasma
concentration, peak values of 70-100%
are usual (Gray et al., 1976; Dische et al.,
1977; Urtasun et al., 1977; Wiltshire
et al., 1978). Thus the plasma MIS con-
centration usually gives a reasonable
estimate of the drug concentration in
the tumour, and hence the theoretical
radiation-enhancement ratio. Secondly,
the neurotoxicity of MIS is dependent
upon the total tissue exposure, which can
be estimated from the area under the
curve of plasma concentration against
time (Dische et al., 1977).
However, serial blood sampling can
be troublesome to the patient and a
non-invasive technique would be ad-
vantageous. Estimation of salivary drug
concentrations has recently proved useful
for a variety of drugs (see reviews by
Speirs, 1977; Horning et al., 1977) includ-
ing methotrexate (Steele et al., 1978). We
have therefore investigated the feasibility
of monitoring the salivary concentration
of MIS in 10 patients with neoplastic
disease under treatment.
M1ETHODS
Clinical details of the patients are sum-
marized in Table I. All gave their informed
consent. MIS was given orally at about 10
a.m. after a light breakfast. The drug was
administered in 500 mg capsules (Roche
Laboratories) so as to give doses as close as
possible to 0-5 g/m2 (low dose), 1U g/m2
(intermediate dose) or 3 g/m2 (high dose).
Blood samples (10 ml) were taken by
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TABLE I.-I)etails of the 10 patients in the study
Surface
Dose of
misoni(lazole
Age Height Weight area , --A
Patienit Sex (years) (m) (ksg) (M'2) (g) (g/m2) (mg/kg) Diagniosis
B.C. M 68 1-77 88 2 (0 1 0 0 . 50 11 4 Ca ltung
lI.C. AM 47 1- 78 91 2 () 1 ( 0 0 50 11 0 Meningeal s.
coma
R.G. MNI 69 1-88 64 1-8 1 0 0-56 15 6 Ca lung
F.F. M 64 1 -79 72 1 9 :3 0 1 58 41-7 Ca lung
E.P. AM 69 1a52
E.E. F 69
1).S. M 41
50 1 4 2-0 1 4:3 40 0 Ca lung
1 57 68 1 7
1 73 66 1-7
1 75 78-5 2 0
1 56
2 5 1 -47
5 0) 2-94
6 0 3 00
3( -8 Cerebial glioma
63 7 Ca lung
76 4 Recurrenit ca.
colon
48 1- 5 4 5 3 -000 9:3-8 Calunlg
1-88 95 2.2 6 5 2 95 68(-4 Cerebhal glioma
Comments
;ar-
One kidney. 'li-
ver metastasis
Wicdespread bone
and liver meta-
stases
Pelvic anid abdlo-
minal vall
metastases
Multiple liver
metastases
Receiving pheny-
toiii therapy
venepunicture immediately before drug ad-
ministration and subsequently at various
times, usually 1, 2, 4, 6, 12 and 24 h after.
Samples of saliva (typically 0-5-2 ml) col-
lected by spitting were also obtained at these
times. For one patient, additional saliva
samples were taken after salivary flow had
been stimulated by giviIng the patient a
piece of lemon to taste. The patient's mouth
was rinsed with water before taking saliva
samples. Results given are for normal
(unstimulated) saliva unless stated otherwise.
Serial tumour samples (typically 5-10 mg)
were obtained by Trucut needle biopsy for 3
patients receiving the highest dose of MIS.
Plasma was collected by centrifugation of
heparinized blood (500 g, 10 min) at 4°C.
Saliva was clarified by centrifugation at
2000 g for 16 h also at 4°C. Tumour-
tissue homogenates (1-20o w/v in double-
distilled water) were prepared by ultrasonic
disintegration, using an MSE 150-watt
ultrasonic disintegrator (Mk 2). Plasma,
saliva and tumour tissue were either
analysed immediately or stored at -20°C
before analysis.
Concentrations of MIS and its 0-demethy-
lated metabolite (1-(2-nitroimidazol-1-yl)-2,3-
propandiol; Ro 05-9963, Roche Laboratories)
in plasma and saliva were determined by
reverse-phase high-performance liquid chro-
matography (HPLC) as described previously
for plasma (Workman et al., 1978). Tumour
homogenates were extracted with methanol
(9 vol) or ethyl acetate (4 vol) and the dried
extracts were taken up in a small volume of
methanol before chromiatography. Analyses
were carried out in duplicate and these rarely
differed by more than 10%.
HPLC estimation of MIS and Ro 05-9963
in saliva was as sensitive and accurate as for
plasma and tissue homogenate. Extraction
efficiency w-as 10000, and no interfering peaks
were detected in control unstimulated saliva.
However, in samples collected after one
patient was given lemon to stimulate sali-
vary flow, a large peak eluted close to the
solvent front. This was probably citric acid,
since this compound alone gave a similar
peak. The interference effectively prevented
the assay of Ro 05-9963, but did not inter-
fere with that of the parent drug.
A number of kinetic parameters were
derived from the plasma and saliva nitroimi-
dazole concentration data. The details of
the calculations used are summarized below.
The elimination of MIS from plasma and
saliva was described by first-order kinetic
equations (see Results). The elimination rate
constant kel is given by the slope of the
elimination phase of the semilog plot of MIS
(log scale) against time (linear scale). The
half-life of the elimination phase (ti) is given
by ln 2/kel Values of kej and t1, with 95%o
confidence limits, were calculated from the
line of best fit estimated by the method of
least-squares linear-regression analysis.
For each plot of plasma or saliva concen-
tration against time (arithmetic coordinates)
Simpson's rule (Crowe & Crowe, 1969) was
D.T. F
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used to calculate the area under the curve
(AUC) between time zero and the last data
point (time t). This AUC value is designated
AUCo 0 t, and t -was usually 24 h.
An estimate of the systemic drug clearance
was made using the equation Cl= D/
AUCo0 where D is the drug dose and
AUCo - is the total area under the curve
betwreen times zero and infinitv. This was
estimated from the equation:
AUCo,0 = AUCo , t + (Ct/k el)
Mwhere Ct is the last-measured drug con-
centration at time t. For this prediction of
drug clearance, we have made the assumption
that the oral dose is completely absorbed.
The saliva/plasma nitroimidazole concen-
tration ratio at a given time was the saliva
concentration divided by the corresponding
plasma concentratioin.
RESULTS
Relationship between plasma and salina
MIS concentration
Fig. I shows plasma and saliva MIS
concentrations plotted on a logarithmic
scale against time on a linear scale for
3 typical patients receiving doses of 0-5,
1-5 and 3-0 g/m2 MIS respectively. It may,
be seen that saliva concentrations were
similar to, though generally rather lower
than, the corresponding plasma concen-
trations. The linear relationship between
plasma and saliva MIS concentration is
illustrated in Fig. 2, which shows the
complete data from all 1 0 patients
(r = 0 93, P < 0 001).
Saliva/plasma MIS r-atio
In general the intra-patient saliva/
plasma concentration ratios exhibited
very little variation, as shown bv the
small standard errors for individual pati-
ents (Table II). There was no change in
this ratio with time after drug adminis-
tration, indicating rapid equilibration
between the 2 fluids. The atypically
large standard error observed for Patient
R.G. is attributed to the fact that the
saliva samples from this patient were
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FmI. I. MAisonidazole coniceintrations in plas-
ma (- OC) and saliva (0 0) of :3
patients receiving 3 oral (loses of MIS.
MIS concentration is plotted on a logarith-
mic scale ani(l time on a linear scale. The
lines of best fit wvere calculated by least-
squares linear-regression anialysis.
contaminated with sputum to a varying
degree.
Table II also illustrates some inter-
patient differences in saliva/plasma ratio,
the range of mean values being 0-59-11 1.
The lowest value was exhibited by
Patient R.G. and was probably due to
the sputum contamination mentioned
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FIG. 2. Relationship between plasnma an(d
saliva MIS concentrations. Each point
in(licates simultaneous plasma andl saliva
concentrations an(l all the data points for a
partictular patient have the same symbol.
Both axes have linear scales. The line, was
fitted by least-squares linear-regression
analysis (r = 0-93, P < 0-001).
above, as lower saliva/plasma ratios were
observed for the heavily contaminated
samples. The mean ± s.d. for the mean
values of the 10 patients was 0 87 ± 0-16
and the coefficient of variation was 18%.
Peak MIS concentration
Peak saliva MIS concentrations were
generally rather lower than those seen
in the plasma (Table II). However, the
times at which the peak concentrations
were observed were very similar. The
median peak time for both plasma and
saliva was 2 h and the interquartile
range was I h in both.
Area under the curve
The AUC values for plasma and saliva
MIS concentration are given in Table II,
and Fig. 3 illustrates the close linear
relationship between the AUCs for the
two body fluids (r- 097, P < 0001).
MIS half-life
After the completion of the absorption
phase, normally lasting 1-2 b, the elimina-
FI(7. 3.-Relationship between area under the
cutrve (AUC) of MIS concentration vs time
for plasma and saliva. Both axes have linear
scales. The line w%,as fittedI by least-squares
linear-regression analysis (r = 0-97, f'
< 0-001).
tion of MIS from plasma and saliva could
be described adequately by first-order
kinetic equations. This is illustrated by
the linearity of the semilog plots in Fig. 1.
V7alues of the elimination half-life calcula-
ted from plasma and saliva data are
shown in Table II. Plasmat. values ranged
from 5-7 to 17-8 h (mean ± s.d. 1241 ±
4.1 h) and these are similar to those
reported previously (Dische et al., 1977;
Wiltshire et al., 1978). Saliva tT values
varied over a similar range of 5.4-21-4 h
(mean ± s.d. 13-0 + 5.4 h). Moreover,
for individual patients the values of
tT for plasma and saliva were in very
good agreement (Table II).
Systemic drug clearance
In some cases systemic drug clearance
is preferred to plasma half-life as a
measure of the efficiency of drug re-
moval from the body (Perrier & Gibaldi,
1974; Wilkinson & Shand, 1975). Values
of systemic clearance calculated from
plasma and saliva data are given in
Table II. For plasma data the values range
from 0 0245 to 0-0494 1/kg/h, with a
mean + s.d. of 0(0361 + 0 0098 1/kg/h. Cl,
values calculated from saliva data were
siniilar, ranging from 0 0238 to 0-0678
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The. 4.- Concentrations of MIS and Ro 05-
9963; in plasma, saliva (,ug/ml) andl biopsy
specimens (/tg/g) in 2 patients who receive(l
'3 g/m2 MIS orally. A, Skin metastasis of
patient C.L. with undifferentiated Ilung
carcinoma. B, Abdominal -wall metastasis
in patient A.T. with adenocarcinoma of
the colon. 0 Plasma MIIS. A Saliva MIS
(broken line). * Tumour MIS. O Plasma
Ro 05 9963:. A Saliva Ro 05-9963.
Ttumourl Ro 05-9963. MITS in stimulate(d
saliva (patienit A onily).
1/kg/h, with a mean i s.d. of 0 0439
001669 1/kg/h. Again the agreement would
be even better if data from Patient R.G.
were omitted.
The inter-patient variation in MIS
plasma half-life (coeff. variation-3 340o)
is similar to that in the systemic clearance
estimated from plasma drug concentration
data (coeff. variation -37%0). Moreover,
these 2 parameters exhibit a close
negative correlation (r -091, P <
0001). The inter-patient variations in
saliva half-life and systemic clearance
estimated from drug concentration data
are also similar (coeff. variation -42%
and 39%o respectively). The correlation
between these parameters is poor (r
0 46, P > 0.1), but is greatly improved
if the data from Patient R.G. are omitted
(r -082, 001 > P> 0001).
0-demethylated metabolite Ro 05-9963
The MIS 0-demethylated metabolite
Ro 05-9963 was detected in the saliva
and plasma of all 10 patients (see Fig. 4).
However, the concentrations observed for
patients receiving the lowest dose (0 5
g/m2) were all lower than 1 5 ,ug/ml. The
precision of the HPLC method decreases
at concentrations below 2 ,ug/ml, so these
data are not presented. Nevertheless,
the general pattern was similar to that
seen at the higher doses. Saliva/plasma
Ro 05-9963 concentration ratios and
AUC values for the patients receiving
1.5 and 3 0 g/m2 are presented in Table
III. The mean z s.d. of the mean saliva/
plasma ratios for the 7 patients receiving
the intermediate and high doses was
0-76 ± 0-21 and th'e coeff. variation was
28%o.
There was a tendency for peak saliva
metabolite concentrations to be seen
later than peak plasma concentrations.
For the 7 patients receiving high and
intermediate doses the median peak times
for plasma and saliva were 6 and 12 h
respectively (the interquartile range was
6 h in both cases).
Tumour concentrations
Tumour concentrations were deter-
mined for 3 of the patients receiving the
highest MIS dose (3 g/m2). Panel A in
Fig. 4 shows the concentrations of MIS
and Ro 05-9963 in serial biopsy specimens
of a skin metastasis in a patient (C.L.)
with an undifferentiated lung carcinoma,
together with corresponding plasma and
saliva data. Two types of saliva collection
were made at 1, 2, 4 and 6 h: a normal
sample followed by a sample taken after
salivary flow was stimulated with lemon
juice. It can be seen that normal and
stimulated saliva had essentially the
same MIS concentration.
The shapes of the concentration vs time
plots for tumour, plasma and saliva were
very, similar. The half-life for the elimina-
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TABLE III.-Summary ofplasma and saliva Ro 05-9963 datafor the 7 patients in the
study receiving 1X5 or 3X0 g/m2 MIS
ATJCo-24 h
(/g/ml/h)
Dose
Patient (g/m2) Plasma Saliva
F.F. 1-5 107 107
E.P. 1-5 180 205
D.T. 1-5 138 103
C.L. 3 0 168 175
A.T. 3 0 201 178
E.E. 3 0 180 90
D.S. 3 0 248 141
* n = 6 except for D.T. (n = 4).
tion of MIS from the tumour was 7-8 h
(5.9-11*6 h), which compares with values
of 9-2 h (8.6-10 0 h) for plasma and 12-7 h
(11 0-15.1 h) for saliva. The estimated
AUC for tumour MIS was 1154 jtg/ml/h
which represents 72% of the plasma AUC
and 820% of the saliva AUC (see Table
II).
The mean i s.e. for the tumour/
plasma MIS ratio was calculated to be
0 73 + 0-06 (n - 4) and the tumour/
saliva (unstimulated) ratio was 0-81 ±
0 15 (n = 4). Ro 05-9963 was only
detected at 4 and 12-25 h and the mean
tumour/plasma and tumour/saliva ratios
were 0 75 and 0-76 respectively.
Panel B in Fig. 4 depicts the concen-
trations of MIS and Ro 05-9963 in serial
biopsy specimens of an abdominal-wall
metastasis in a patient (A.T.) with a recur-
rent colon adenocarcinoma. The estimated
AUC for tumour MIS was 1205 Htg/ml/h
which represents 60% of the plasma AUC
and 64% ofthe saliva AUC (see Table II).
The half-life for elimination of MIS
from the tumour was 12-2 h (10-4-14 7 h)
which compares with values of 16-2 h
(14-0-19-4 h) for plasma and 17-7 h (13.4-
26-1 h) for saliva. The mean ± s.e. for
the tumour/plasma MIS ratio was 0-64 ±
0 07 (n - 4) and for the tumour/saliva
ratio 0 73 ± 0 11 (n - 4). Ro 05-9963
was detected in the tumour at 2, 4, 12 and
24 h and the mean tumour/plasma and
tumour/saliva ratios (± s.e.) were 1-07 ±
0 28 (n = 4) and 1-03 ± 0 17 (n = 4)
respectively.
Table IV summarizes the results ob-
tained for serial biopsy specimens of a
skin metastasis in a patient (E.E.) with
an undifferentiated bronchial carcinoma,
together with corresponding plasma and
saliva data. In this case the tumour,
plasma and saliva nitroimidazole con-
centrations were similar at 2 and 4 h,
but at 12 and 24 h tumour concentrations
were considerably higher than in plasma
and saliva.
DISCUSSION
The present studies have demonstrated
a good linear correlation between the
TABLE IV.-Concentrations of MIS and Ro 05-9963 in plasma and saliva and in biopsy
specimens of a skin metastasis in a patient (E.E.) with an undifferentiated bronchial
carcinoma who received 3 g/M2 MIS orally
Concentration of 2-nitroimidazole
Plasma
MIS Ro 05-9963
(yg/ml)
129
112
60
34
6
10
8
6
Saliva
MIS Ro 05-9963
(Ktg/ml)
76
66
37
20
2
3
4
3
Tumour
MIS Ro 05-9963
(pg1mg)
91
86
215
77
5
8
30
16
Saliva/plasma
ratio
(mean + s.e.*)
0-87+0-15
1-09+0 19
0 fi5±0 07
0 88±0 15
0 80+0-11
0 47±0 16
0 56±0 03
Time
(h)
2
4-5
12
24
48
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concentrations of MIS in plasma and
mixed saliva. Intra-patient differences in
saliva/plasma MIS ratio were small and
did not vary appreciably with time after
drug administration. However, some inter-
patient variation was noted, with saliva/
plasma ratios ranging from 0 59 to 1.11.
On the other hand, with the exception of
2 patients, the mean saliva/plasma ratios
were all greater than 0O8.
A number of factors may be involved
in determining saliva/plasma drug ratios.
These include the mol. wt of the drug
(or membrane porosity); the pKa, parti-
tion coefficient and protein-binding pro-
perties of the drug; plasma and saliva
pH; salivary flox rate; the state of oral
hygiene; and the nature and concentra-
tion of plasma and saliva constituents,
particularly proteins and oral debris.
Some of these factors have been reviewed
briefly by Schanker (1964) and Speirs
(1977).
The physicochemical properties of MIS
are such that good penetration through
cell membranes would be expected.
Firstly, MIS is a comparatively small
molecule (mol. wt 201). Secondly, on the
basis of previous studies on related nitro-
imidazoles (Gallo et al., 1964), it is clear
that MIS will be un-ionized in the physio-
logical pH range. Thirdly, the octanol/
water partition coefficient for MIS at
pH 7*4 is 0 43 (Adams et al., 1976), which
indicates that the drug is somewhat
lipophilic. The intra-patient saliva/plasma
misonidazole ratios were independent of
plasma MIS concentration, which suggests
that the transfer of the drug from plasma
to saliva probably occurs by passive
diffusion.
Salivary flow rate is a possible factor
affecting saliva/plasma ratios, but the
present studies suggested that this was
not so for MIS.
Salivary pH is not constant, but
tends to be lower than that of the plasma.
In a series of fresh saliva samples from
10 laboratory staff, we found that the
pH varied from 6-4 to 7-5 (mean 6.9).
Similar findings have been reported by
others (Kostlin & Rauch, 1957; Mason
& Chisholm, 1975). However, MIS is
completely un-ionized over this pH range,
and differences in pH between plasma and
saliva would not affect the distribution of
MIS between these fluids.
Binding of drugs to plasma proteins
can result in saliva/plasma ratios less
than unity. Previous studies on a variety
of drugs have shown good agreement
between the drug concentration in saliva
and the concentration of non-protein-
bound drug in plasma or serum (reviewed
by Speirs, 1977; Horning et al., 1977).
However, ultrafiltration analysis has
shown that for MIS there is no measurable
binding to plasma proteins (T. R. Marten
& C. J. Little, personal communication).
In the present study we found that, in
one patient, contamination of the saliva
with sputum resulted in low saliva MIS
concentrations. However, this could not
account for the variation in plasma/
saliva ratios in patients able to provide
sputum-free saliva. It therefore seems
likely that this inter-patient variation
may be due to other differences in the
nature and concentration of saliva con-
stituents between patients. Mixed saliva
consists of secretions from the parotid,
submandibular, sublingual and other min-
or glands, together with gingival fluid,
desquamated epithelial cells, bacteria and
other oral debris (Mason & Chisholm,
1975; Stephen & Speirs, 1976; Speirs,
1977). The various secretions show some
differences in composition, and differences
between gingival fluid and the glandular
secretions are particularly marked (Mason
& Chisholm, 1975). Moreover, the con-
centrations of certain antibiotics are
higher in gingival fluid than in glandular
saliva (MacFarlane, et al., 1974). Adsorp-
tion of drugs by oral debris may also
affect their concentration in mixed saliva
(Paxton, et al., 1976).
In view of the usefulness of pharma-
cokinetic determinations for predicting
the possible toxic and therapeutic effects
of MIS in individual patients (Dische et
al., 1977; Wiltshire et al., 1978), it isMONITORING SALIVARY MISONIDAZOLE
pertinent to discuss the relative merits of
saliva and plasma as the sampled bio-
logical fluid. Saliva and plasma are
equally suitable for HPLC analysis, and
we have been able to analyse samples as
small as 20pl. However, other analytical
methods may require much larger sample
volumes, in which case saliva sampling
might be advantageous. This non-invasive
technique may be particularly suitable
for small children and for patients with
inaccessible or thrombosed veins. In
addition, mixed-saliva sampling does not
require trained personnel. Indeed, samples
could even be taken by the patient, which
would facilitate pharmacokinetic investi-
gations on patients taking the drug at
home, and might be used to assess patient
compliance in clinical trials and routine
therapy.
The values of ti for the elimination of
MIS from plasma and saliva showed very
good agreement, and we have also shown
a good linear correlation between plasma
and saliva MIS concentration and between
plasma and saliva MIS AUC values. The
variation in saliva/plasma ratio between
patients (and possibly within patients on
different occasions) precludes direct extra-
polation from saliva to plasma on the
basis of saliva data alone. However, it
should in practice be possible to use saliva
monitoring to identify high-risk patients
with abnormally high plasma levels.
In addition, saliva data can be used to
estimate systemic drug clearance, and this
parameter exhibits a close negative cor-
relation with the elimination half-life.
W\Te have speculated that at least part
of the inter-patient variations in saliva/
plasma ratios may be due to the variable
composition of mixed saliva. To avoid
this problem, Stephen & Speirs (1976)
recommended the collection of individual
components of mixed saliva, for which
techniques are available (Mason & Chis-
holm, 1975; Stephen & Speirs, 1976).
However, in using these methods much of
the simplicity of mixed-saliva sampling
would be lost.
In contrast to our experience with
healthy volunteers, some of the patients
in the present study had difficulty in
producing saliva samples. Since salivary
MIS concentration appears to be inde-
pendent of salivary flow rate, we recom-
mend that some form ofsaliva stimulation
be used in future studies. Lemon juice
and citric acid are unsuitable if the
present HPLC assay technique is used,
but may be suitable for other analytical
methods. Other methods ofsaliva stimula-
tion usually involve chewing or sucking
some inert material; however, care must
be taken to avoid both contamination
of the saliva and loss of drug by adsorp-
tion (Stephen & Speirs, 1976).
An important disadvantage of saliva
sampling is that it is unsuitable for oral
medications other than capsule formula-
tions, because onlythe latterpreventdirect
contamination of saliva by the drug
(Speirs et al., 1971; Graham & Rowland,
1972). MIS has previously been supplied
in both tablet and capsule formula-
tions. Moreover, because ofthe large doses
involved, some patients prefer to take the
drug as a solution. In the present study we
have used capsules only, and we would
not recommend the use of saliva sampling
for other oral formulations.
To attempt to predict the possible
therapeutic effect of MIS, the concentra-
tion of radiosensitizing species in the
tumour must be known. In the present
study we were able to determine tumour
concentrations of MIS and Ro 05-9963 as
well as data for plasma and saliva, in
3 patients. In general, the tumour
nitroimidazole concentrations were within
the range 50-100% of the corresponding
plasma concentrations. This is in agree-
ment with previous findings (Dische
et al., 1977; Wiltshire et al., 1978). How-
ever, in one patient, tumour levels at
12 and 24 h were considerably higher
than those in plasma. Comparison of
tumour, plasma and saliva data for this
small sample of patients suggests that
saliva data are at least as good as plasma
data for predicting tumour nitroimi-
dazole concentrations.
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